NPJ Breast Cancer最新文献_第9页

Impact of endocrine therapy regimens for early-stage ER+/HER2-breast cancer on contralateral breast cancer risk. 早期ER+/ her2乳腺癌内分泌治疗方案对对侧乳腺癌风险的影响

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-03-26 DOI: 10.1038/s41523-025-00746-7

Swarnavo Sarkar, Clyde Schechter, Allison W Kurian, Jennifer L Caswell-Jin, Jinani Jayasekera, Jeanne S Mandelblatt

{"title":"Impact of endocrine therapy regimens for early-stage ER+/HER2-breast cancer on contralateral breast cancer risk.","authors":"Swarnavo Sarkar, Clyde Schechter, Allison W Kurian, Jennifer L Caswell-Jin, Jinani Jayasekera, Jeanne S Mandelblatt","doi":"10.1038/s41523-025-00746-7","DOIUrl":"10.1038/s41523-025-00746-7","url":null,"abstract":"Endocrine therapy for breast cancer may reduce the risk of contralateral breast cancer (CBC). However, there are no published estimates quantifying the lifetime outcomes by age at primary diagnosis, regimen, or duration. Here, we adapted an established Cancer Intervention and Surveillance Network (CISNET) model to simulate life histories of multiple US female birth-cohorts diagnosed with stage 0-III ER+/HER2- breast cancer receiving different durations (none, 2.5, 5, 10 years) of two endocrine therapy regimens (aromatase inhibitors or tamoxifen; including ovarian-function suppression for premenopausal women). As expected, greater duration of endocrine therapy led to more avoided CBC cases, as did aromatase inhibitors over tamoxifen, but the numbers varied greatly by the age of diagnosis. The maximum number of CBC were avoided using 10-year aromatase inhibitor regimens (6.0 vs. 11.2 for no adjuvant therapy, per 100 women with ER+/HER2- breast cancer). For the 5-year aromatase inhibitors therapy, women <45 years had the largest reduction in CBC cases (5.0/100), which dropped to 2.7/100 for women at 75+ years. Quantification of the lifetime risk of CBC for specific endocrine therapy types and duration is helpful for weighing therapeutic options. The risk of breast cancer death has a larger weight, but inclusion of the risk of CBC increases the separation between different therapy options.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"30"},"PeriodicalIF":6.5,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11947086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143720883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic difference between early breast cancer patients with HER2 low and HER2 zero status. HER2低和HER2零状态早期乳腺癌患者的预后差异

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-03-26 DOI: 10.1038/s41523-025-00737-8

Chihwan David Cha, Kyung Eun Kim, Jungbin Kim, Eunhae Um, Nayeon Choi, Jungsun Lee, Geumhee Gwak, Jae Il Kim, Min Sung Chung

{"title":"Prognostic difference between early breast cancer patients with HER2 low and HER2 zero status.","authors":"Chihwan David Cha, Kyung Eun Kim, Jungbin Kim, Eunhae Um, Nayeon Choi, Jungsun Lee, Geumhee Gwak, Jae Il Kim, Min Sung Chung","doi":"10.1038/s41523-025-00737-8","DOIUrl":"10.1038/s41523-025-00737-8","url":null,"abstract":"We aimed to investigate the differences in prognosis between patients with HER2-low and HER2-zero status. This retrospective cohort study conducted at multi-institution included 1627 patients diagnosed with HER2-low or HER2-zero breast cancer (stages I-III). Survival analysis after propensity score matching was used. In total, 445 patients with HER2-low and 707 patients with HER2-zero status were included. The median follow-up was 92.7 months. Locoregional and distant recurrence-free survival were comparable between patients with HER2-low and HER2-zero status (p = 0.872, p = 0.746, respectively). HER2-low status did not affect overall survival. However, in subgroups with lymph node metastases, patients with HER2-low status showed better recurrence-free survival compared with that of patients with HER2-zero status (p = 0.033). In conclusion, survival outcomes were comparable between patients with HER2-low and HER2-zero breast cancer. More studies are needed to validate our findings and examine the biological mechanism underlying these prognostic differences.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"31"},"PeriodicalIF":6.5,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11947260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143720885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer. 一项将HER2定向树突状细胞纳入早期HER2+ER-乳腺癌新辅助治疗的初步研究。

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-03-17 DOI: 10.1038/s41523-025-00742-x

Hatem Soliman, Amy Aldrich, Neveen Abdo, Hyo Han, Aixa Soyano, Ricardo Costa, Avan Armaghani, John Kiluk, Nazanin Khakpour, Marie Catherine Lee, Susan Hoover, Christine Laronga, Bethany Niell, Blaise Mooney, Robert Jared Weinfurtner, Marilin Rosa, Brian Czerniecki

{"title":"A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer.","authors":"Hatem Soliman, Amy Aldrich, Neveen Abdo, Hyo Han, Aixa Soyano, Ricardo Costa, Avan Armaghani, John Kiluk, Nazanin Khakpour, Marie Catherine Lee, Susan Hoover, Christine Laronga, Bethany Niell, Blaise Mooney, Robert Jared Weinfurtner, Marilin Rosa, Brian Czerniecki","doi":"10.1038/s41523-025-00742-x","DOIUrl":"10.1038/s41523-025-00742-x","url":null,"abstract":"Type 1 dendritic cell vaccines targeting HER2 (HER2-DC1) reinvigorates antitumor immunity which correlates with neoadjuvant therapy response. A pilot trial (clinicaltrials.gov,NCT03387553,1/2/2018) using HER2-DC1 pre-neoadjuvant therapy evaluated feasibility/safety and pathologic response rates/immunogenicity. Stage II-III ER-HER2+ breast cancer patients prescribed neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) were enrolled. HER2-DC1 (2×107 cells/vaccine) was given for 3 weeks prior to chemotherapy intranodal (IN) 1x/week (Arm A), IN 2x/week (Arm B), and 2x/week alternating intratumoral (IT) and IN (Arm C). HER2 ELISPOT counts (EHC) and immunofluorescence analysis of biopsies were performed. Six patients enrolled in Arms A and B, 18 patients in Arm C. Neoadjuvant HER2-DC1 demonstrated no unexpected safety signals. Pathologic complete response rates (pCR) across arms A, B, C were 42.8%, 66.6%, and 72.7%. Intranodal HER2-DC1 increased EHC, but IT + IN HER2-DC1 reduced EHC, possibly due to increased T cell tumor trafficking. Immunofluorescence showed increased T cell infiltration following IT + IN injections. Additional IT HER2-DC1 investigation is warranted.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"29"},"PeriodicalIF":6.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11914126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143649641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies. 三阴性乳腺癌（TNBC）患者动态her2低状态及重复活检的影响

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-03-11 DOI: 10.1038/s41523-025-00741-y

Yael Bar, Geoffrey Fell, Aylin Dedeoglu, Natalie Moffett, Neelima Vidula, Laura Spring, Seth A Wander, Aditya Bardia, Naomi Ko, Beverly Moy, Leif W Ellisen, Steven J Isakoff

{"title":"Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies.","authors":"Yael Bar, Geoffrey Fell, Aylin Dedeoglu, Natalie Moffett, Neelima Vidula, Laura Spring, Seth A Wander, Aditya Bardia, Naomi Ko, Beverly Moy, Leif W Ellisen, Steven J Isakoff","doi":"10.1038/s41523-025-00741-y","DOIUrl":"10.1038/s41523-025-00741-y","url":null,"abstract":"Trastuzumab deruxtecan (T-DXd) is approved for HER2-low (HER2 immunohistochemistry (IHC)1+ or 2+ with non-amplified in situ hybridization (ISH)), but not HER2-0 (IHC 0) metastatic breast cancer. The impact of repeat biopsies (Bxs) in identifying new potential candidates with triple negative breast cancer (TNBC) for T-DXd treatment remains unknown. 512 consecutive patients with TNBC at diagnosis were included in the study cohort. Bxs were categorized as core, surgical, or metastatic based on the timing and method of biopsy (Bx) acquisition, and the total number of Bxs was determined for each patient. Additionally, matched biopsies were identified, and the rate of discordance in HER2 status was calculated. The proportion of patients with at least one HER2-low result increased as the number of successive Bxs increased [59%, 73%, 83%, 83%, and 100% when 1 (196 patients), 2 (231 patients), 3 (48 patients), 4 (29 patients), and ≥ 5 (8 patients) Bxs were obtained, respectively]. Among patients without a prior HER2-low result, approximately one-third demonstrated HER2-low status with each additional successive Bx. HER2 status exhibited variability between matched Bxs, with observed discordance rates of 26%, 44%, and 33% between matched core-surgical, early-metastatic, and two metastatic matched Bxs, respectively. Our findings indicate that HER2 status can vary between different Bxs taken during the disease course of patients with TNBC with the highest discordance rate observed between the primary and metastatic Bxs. For patients with metastastic HER2-0 TNBC, repeat Bxs can increase the chance of obtaining a HER2-low result, thereby offering patients a promising therapeutic option.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"27"},"PeriodicalIF":6.5,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143605837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Population-specific patterns in assessing molecular subtypes of young black females with triple-negative breast cancer. 评估年轻黑人女性三阴性乳腺癌分子亚型的人群特异性模式。

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-03-11 DOI: 10.1038/s41523-025-00731-0

Padma Sheila Rajagopal, Sonya Reid, Run Fan, Lindsay Venton, Anne Weidner, Mya L Roberson, Susan Vadaparampil, Xuefeng Wang, Sean Yoder, Marilin Rosa, Melinda Sanders, Paula Gonzalez-Ericsson, Jibril Hirbo, Jennifer G Whisenant, Jennifer Pietenpol, Fei Ye, Tuya Pal, Brian D Lehmann

{"title":"Population-specific patterns in assessing molecular subtypes of young black females with triple-negative breast cancer.","authors":"Padma Sheila Rajagopal, Sonya Reid, Run Fan, Lindsay Venton, Anne Weidner, Mya L Roberson, Susan Vadaparampil, Xuefeng Wang, Sean Yoder, Marilin Rosa, Melinda Sanders, Paula Gonzalez-Ericsson, Jibril Hirbo, Jennifer G Whisenant, Jennifer Pietenpol, Fei Ye, Tuya Pal, Brian D Lehmann","doi":"10.1038/s41523-025-00731-0","DOIUrl":"10.1038/s41523-025-00731-0","url":null,"abstract":"We determined triple-negative breast cancer (TNBC) subtypes, genetic ancestry, and immune features in a cohort of self-reported Black females with TNBC diagnosed at or below age 50. Among 104 tumors, 34.6% were basal-like 1 (BL1), 17.3% basal-like 2 (BL2), 9.6% luminal androgen receptor (LAR), 26.9% mesenchymal (M), and 11.5% unsubtyped (UNS). Subtypes resembled those seen in Europeans or East Asians, with less LAR (9.6% vs. 14.6-24.4%) and more UNS (11.5% vs. 0-7.5%). \"High\" proportion of West African ancestry was associated with more LAR (14.9% vs. 4.9%) and less M (25.5% vs. 34.2%). M demonstrated reduced immune activity and was marginally associated with worse overall survival in a multivariate model including stage, West African ancestry, BMI, and TILs, meriting future research. Our study is the largest to date of TNBC subtypes in young Black females. These results reinforce TNBC subtypes' application across populations and potential use as a prognostic biomarker.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"28"},"PeriodicalIF":6.5,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143605841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prosigna Risk of Recurrence score and intrinsic subtypes are associated with adjuvant anthracycline chemotherapy benefit in high-risk breast cancer. Prosigna复发风险评分和内在亚型与高危乳腺癌蒽环类辅助化疗的获益相关。

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-03-10 DOI: 10.1038/s41523-025-00738-7

Maj-Britt Jensen, Torsten O Nielsen, John Bartlett, Anne-Vibeke Lænkholm, Lois Shepherd, Bent Ejlertsen

{"title":"Prosigna Risk of Recurrence score and intrinsic subtypes are associated with adjuvant anthracycline chemotherapy benefit in high-risk breast cancer.","authors":"Maj-Britt Jensen, Torsten O Nielsen, John Bartlett, Anne-Vibeke Lænkholm, Lois Shepherd, Bent Ejlertsen","doi":"10.1038/s41523-025-00738-7","DOIUrl":"10.1038/s41523-025-00738-7","url":null,"abstract":"NCIC-CTG MA.5 and DBCG 89D are symmetrically designed randomized trials comparing adjuvant cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in high-risk breast cancer patients. In a joint analysis we evaluate the predictive value in terms of anthracycline benefit of molecular subtyping by PAM50. A statistically significant interaction (P = 0.008) between continuous Risk of Recurrence (ROR) score and treatment regimen is evident, translating into a clear distinct treatment effect according to ROR score category with HR 0.51 for ROR score ≥ 72 and HR 1.10 for ROR score < 52 (Pinteraction = 0.004). The analysis provides evidence of the benefit from anthracycline in HER2-enriched subtype; for patients with discordance of HER2 subtype and clinical HER2 status, HER2-enriched subtype was predictive of anthracycline benefit whereas clinical HER2 positive status was not. Anthracycline-based adjuvant chemotherapy may safely be withheld for patients with a low ROR score while the benefit increases with increasing ROR score.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"26"},"PeriodicalIF":6.5,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11894038/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer. 通过乳腺癌体细胞拷贝数畸变实现ctDNA的敏感和精确检测。

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-03-08 DOI: 10.1038/s41523-025-00739-6

Riccardo Scandino, Agostina Nardone, Nicola Casiraghi, Francesca Galardi, Mattia Genovese, Dario Romagnoli, Marta Paoli, Chiara Biagioni, Andrea Tonina, Ilenia Migliaccio, Marta Pestrin, Erica Moretti, Luca Malorni, Laura Biganzoli, Matteo Benelli, Alessandro Romanel

{"title":"Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer.","authors":"Riccardo Scandino, Agostina Nardone, Nicola Casiraghi, Francesca Galardi, Mattia Genovese, Dario Romagnoli, Marta Paoli, Chiara Biagioni, Andrea Tonina, Ilenia Migliaccio, Marta Pestrin, Erica Moretti, Luca Malorni, Laura Biganzoli, Matteo Benelli, Alessandro Romanel","doi":"10.1038/s41523-025-00739-6","DOIUrl":"10.1038/s41523-025-00739-6","url":null,"abstract":"Cell-free DNA (cfDNA) extracted from peripheral blood has emerged as a crucial biomarker source in oncology research. To enhance the detection of somatic copy number alterations (SCNAs) and circulating tumor DNA (ctDNA), we developed eSENSES, a 2 Mb breast cancer-targeted NGS panel. It includes 15,000 genome-wide SNPs, 500 focal SNPs in breast cancer driver regions, and exons from 81 commonly altered genes, alongside a custom computational approach. We assessed the performance of eSENSES using both synthetic and clinical samples showing that eSENSES can detect ctDNA levels below 1%, exhibiting high sensitivity and specificity at 2-3% ctDNA levels. In patients with metastatic breast cancer, ctDNA estimations correlated with disease progression. When compared with other technologies and state-of-the-art approaches, eSENSES demonstrated enhanced performance. eSENSES provides a reliable, powerful and cost-effective tool for monitoring disease progression and guiding therapeutic decisions in breast cancer patients.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"25"},"PeriodicalIF":6.5,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets. CALGB 40603（联盟）和公共三阴性乳腺癌数据集的预后和分子多平台分析

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-03-08 DOI: 10.1038/s41523-025-00740-z

Brooke M Felsheim, Aranzazu Fernandez-Martinez, Cheng Fan, Adam D Pfefferle, Michele C Hayward, Katherine A Hoadley, Naim U Rashid, Sara M Tolaney, George Somlo, Lisa A Carey, William M Sikov, Charles M Perou

{"title":"Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets.","authors":"Brooke M Felsheim, Aranzazu Fernandez-Martinez, Cheng Fan, Adam D Pfefferle, Michele C Hayward, Katherine A Hoadley, Naim U Rashid, Sara M Tolaney, George Somlo, Lisa A Carey, William M Sikov, Charles M Perou","doi":"10.1038/s41523-025-00740-z","DOIUrl":"10.1038/s41523-025-00740-z","url":null,"abstract":"Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous disease that remains challenging to target with traditional therapies and to predict risk. We provide a comprehensive characterization of 238 stage II-III TNBC tumors with paired RNA and DNA sequencing data from the CALGB 40603 (Alliance) clinical trial, along with 448 stage II-III TNBC tumors with paired RNA and DNA data from three additional datasets. We identify DNA mutations associated with RNA-based subtypes, specific TP53 missense mutations compatible with potential neoantigen activity, and a consistently highly altered copy number landscape. We train exploratory multi-modal elastic net models of TNBC patient overall survival to determine the added impact of DNA-based features to RNA and clinical features. We find that mutations and copy number show little to no prognostic value, while RNA expression features, including signatures of T cell and B cell activity, along with stage, improve stratification of TNBC survival risk.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"24"},"PeriodicalIF":6.5,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial. EORTC 10994/BIG 1-00早期乳腺癌试验中基于机器学习的肿瘤免疫微环境空间表征

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-03-07 DOI: 10.1038/s41523-025-00730-1

Ioannis Zerdes, Alexios Matikas, Artur Mezheyeuski, Georgios Manikis, Balazs Acs, Hemming Johansson, Ceren Boyaci, Caroline Boman, Coralie Poncet, Michail Ignatiadis, Yalai Bai, David L Rimm, David Cameron, Hervé Bonnefoi, Jonas Bergh, Gaetan MacGrogan, Theodoros Foukakis

{"title":"Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial.","authors":"Ioannis Zerdes, Alexios Matikas, Artur Mezheyeuski, Georgios Manikis, Balazs Acs, Hemming Johansson, Ceren Boyaci, Caroline Boman, Coralie Poncet, Michail Ignatiadis, Yalai Bai, David L Rimm, David Cameron, Hervé Bonnefoi, Jonas Bergh, Gaetan MacGrogan, Theodoros Foukakis","doi":"10.1038/s41523-025-00730-1","DOIUrl":"10.1038/s41523-025-00730-1","url":null,"abstract":"Breast cancer (BC) represents a heterogeneous ecosystem and elucidation of tumor microenvironment components remains essential. Our study aimed to depict the composition and prognostic correlates of immune infiltrate in early BC, at a multiplex and spatial resolution. Pretreatment tumor biopsies from patients enrolled in the EORTC 10994/BIG 1-00 randomized phase III neoadjuvant trial (NCT00017095) were used; the CNN11 classifier for H&E-based digital TILs (dTILs) quantification and multiplex immunofluorescence were applied, coupled with machine learning (ML)-based spatial features. dTILs were higher in the triple-negative (TN) subtype, and associated with pathological complete response (pCR) in the whole cohort. Total CD4+ and intra-tumoral CD8+ T-cells expression was associated with pCR. Higher immune-tumor cell colocalization was observed in TN tumors of patients achieving pCR. Immune cell subsets were enriched in TP53-mutated tumors. Our results indicate the feasibility of ML-based algorithms for immune infiltrate characterization and the prognostic implications of its abundance and tumor-host interactions.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"23"},"PeriodicalIF":6.5,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11889191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases. sacituzumab govitecan在中枢神经系统转移的乳腺癌患者中的真实世界结果。

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-03-05 DOI: 10.1038/s41523-025-00736-9

Thomas Grinda, Stefania Morganti, Liangge Hsu, Tae-Kyung Yoo, Ross J Kusmick, Ayal A Aizer, Antonio Giordano, Jose P Leone, Melissa Hughes, Sara M Tolaney, Nancy U Lin, Sarah L Sammons

引用次数: 0